Search Results

There are 14290 results for: content related to: Analysis of CYP 2C9*2 , CYP 2C9*3 and VKORC 1 -1639 G>A polymorphisms in a population from S outh- E astern E urope

  1. You have free access to this content
    Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study

    British Journal of Haematology

    Volume 167, Issue 4, November 2014, Pages: 547–553, Sophie Brunner-Ziegler, Bernd Jilma, Dominic Magirr, Raute Sunder-Plassmann, Georgiana-Aura Giurgea, Alexandra Hammer, Christian Margeta, Martin Brunner, Renate Koppensteiner and Christine Mannhalter

    Version of Record online : 21 AUG 2014, DOI: 10.1111/bjh.13082

  2. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes

    Journal of Thrombosis and Haemostasis

    E. V. Baranova, T. I. Verhoef, G. Ragia, S. le Cessie, F. W. Asselbergs, A. de Boer, V. G. Manolopoulos, A. H. Maitland-van der Zee and for the EU-PACT group

    Version of Record online : 17 FEB 2017, DOI: 10.1111/jth.13615

  3. Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population

    European Journal of Haematology

    Volume 93, Issue 4, October 2014, Pages: 320–328, Ľubica Krajčíová, Robert Petrovič, Ľudmila Déžiová, Ján Chandoga and Peter Turčáni

    Version of Record online : 12 MAY 2014, DOI: 10.1111/ejh.12348

  4. You have free access to this content
    Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione

    British Journal of Clinical Pharmacology

    Volume 73, Issue 3, March 2012, Pages: 428–436, Karine Lacut, Estelle Ayme-Dietrich, Lenaick Gourhant, Elise Poulhazan, Marion Andro, Laurent Becquemont, Dominique Mottier, Gregoire Le Gal and Celine Verstuyft

    Version of Record online : 13 FEB 2012, DOI: 10.1111/j.1365-2125.2011.04095.x

  5. Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 4, April 2009, Pages: 379–386, M Teichert, RHN van Schaik, A Hofman, AG Uitterlinden, PAGM de Smet, BHCh Stricker and LE Visser

    Version of Record online : 18 FEB 2009, DOI: 10.1038/clpt.2008.294

  6. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

    Clinical Pharmacology & Therapeutics

    Volume 81, Issue 2, February 2007, Pages: 185–193, T Schalekamp, B P Brassé, J F M Roijers, E van Meegen, F J M van der Meer, E M van Wijk, A C G Egberts and A de Boer

    Version of Record online : 27 DEC 2006, DOI: 10.1038/sj.clpt.6100036

  7. Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1418–1428, Ms Maria O. Esmerian, Dr Zahi Mitri, Dr Mohammad-Zuheir Habbal, Mr Eddy Geryess, Dr Ghazi Zaatari, Dr Samir Alam, Dr Hadi N. Skouri, Dr Rami A. Mahfouz, Dr Ali Taher and Dr Nathalie K. Zgheib

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010382910

  8. Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 12, December 2011, Pages: 1192–1207, Dr. Larisa H. Cavallari, Dr. Jaekyu Shin and Dr. Minoli A. Perera

    Version of Record online : 20 JAN 2012, DOI: 10.1592/phco.31.12.1192

  9. You have free access to this content
    Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 4, April 2012, Pages: 606–614, T. I. VERHOEF, W. K. REDEKOP, M. M. BUIKEMA, T. SCHALEKAMP, F. J. M. VAN DER MEER, S LE CESSIE, J. A. M. WESSELS, R. M. F. VAN SCHIE, A. DE BOER, M. TEICHERT, L. E. VISSER, A. H. MAITLAND-VAN DER ZEE and ON BEHALF OF THE EU-PACT GROUP

    Version of Record online : 30 MAR 2012, DOI: 10.1111/j.1538-7836.2012.04633.x

  10. You have free access to this content
    Clinical significance of CYP2C9-status guided valproic acid therapy in children

    Epilepsia

    Volume 56, Issue 6, June 2015, Pages: 849–855, Tamás Bűdi, Katalin Tóth, Andrea Nagy, Zsuzsa Szever, Ádám Kiss, Manna Temesvári, Edit Háfra, Miklós Garami, Adrienn Tapodi and Katalin Monostory

    Version of Record online : 13 MAY 2015, DOI: 10.1111/epi.13011

  11. You have free access to this content
    The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population

    British Journal of Haematology

    Volume 165, Issue 6, June 2014, Pages: 832–835, Susan I. Vear, Gregory D. Ayers, Sara L. Van Driest, Robert F. Sidonio, Charles Michael Stein and Richard H. Ho

    Version of Record online : 6 MAR 2014, DOI: 10.1111/bjh.12817

  12. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

    Clinical Pharmacology & Therapeutics

    Volume 80, Issue 4, October 2006, Pages: 346–355, Lai-San Tham, Boon-Cher Goh, Anne Nafziger, Jia-Yi Guo, Ling-Zhi Wang, Richie Soong and Soo-Chin Lee

    Version of Record online : 22 OCT 2006, DOI: 10.1016/j.clpt.2006.06.009

  13. Warfarin Pharmacogenetics

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 9, September 2008, Pages: 1084–1097, Dr. Nita A. Limdi and Dr. David L. Veenstra

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.9.1084

  14. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 4, April 2010, Pages: 459–464, L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel and J A Johnson

    Version of Record online : 13 JAN 2010, DOI: 10.1038/clpt.2009.223

  15. You have free access to this content
    Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis

    Cardiovascular Therapeutics

    Volume 35, Issue 1, February 2017, Pages: 26–32, Jinhua Zhang, Lihong Tian, Jinlong Huang, Sihan Huang, Tingting Chai and Jianzhen Shen

    Version of Record online : 13 DEC 2016, DOI: 10.1111/1755-5922.12230

  16. The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 3, March 2011, Pages: 408–415, MA Perera, E Gamazon, LH Cavallari, SR Patel, S Poindexter, RA Kittles, D Nicolae and NJ Cox

    Version of Record online : 26 JAN 2011, DOI: 10.1038/clpt.2010.322

  17. In vitro assessment of 39 CYP2C9 variants found in the Chinese population on the metabolism of the model substrate fluoxetine and a summary of their effects on other substrates

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 3, June 2015, Pages: 320–327, Y. Ji, S. Chen, L. Zhao, P. Pan, L. Wang, J. Cai, D. Dai, G. Hu, J. P. Cai and H. Huang

    Version of Record online : 17 APR 2015, DOI: 10.1111/jcpt.12267

  18. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

    Clinical Pharmacology & Therapeutics

    Volume 79, Issue 4, April 2006, Pages: 291–302, Christina L. Aquilante, Taimour Y. Langaee, Larry M. Lopez, Hossein N. Yarandi, Jennifer S. Tromberg, Dagmara Mohuczy, Katherine L. Gaston, Cassandra D. Waddell, Mark J. Chirico and Julie A. Johnson

    Version of Record online : 16 APR 2006, DOI: 10.1016/j.clpt.2005.11.011

  19. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation

    Clinical Pharmacology & Therapeutics

    Volume 80, Issue 1, July 2006, Pages: 13–22, Tom Schalekamp, Bjorn P Brassé, Janine F M Roijers, Youssef Chahid, Johanna H H van Geest-Daalderop, Hanneke de Vries-Goldschmeding, Eduard M van Wijk, Antoine C G Egberts and Anthonius de Boer

    Version of Record online : 3 JUL 2006, DOI: 10.1016/j.clpt.2006.04.006

  20. You have free access to this content
    Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 8, August 2015, Pages: 1436–1440, S. Abohelaika, H. Wynne, P. Avery and F. Kamali

    Version of Record online : 19 JUN 2015, DOI: 10.1111/jth.13014